XTalks
MAY 23, 2024
Companies specializing in dermatology and skincare have developed a range of products aimed at protecting the skin from harmful UV rays. In fact, tools such as dermatoscopes, digital imaging systems and artificial intelligence (AI)-powered diagnostic tools have become integral to dermatological practice.
Drug Discovery World
DECEMBER 11, 2023
MC2-25 CKD is a first-in-class drug candidate and could represent a potential breakthrough in the understanding and treatment of urea associated skin diseases. The active component of MC2-25 CKD is a di-peptide, which is formulated in cream based on MC2 Therapeutics’ formulation and drug delivery system PAD Technology.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Roots Analysis
MARCH 3, 2022
Since the approval of Soliris® in 2007, an anti-C5 antibody, the field of complement drug discovery has gained significant attention. Currently, nine complement therapeutics are commercially available, while around 190 molecules are under development for various disease indications. Next Generation Complement Therapeutics. Web: [link].
The Pharma Data
MARCH 3, 2021
Mylan) and Kindeva Drug Delivery L.P. The Company’s growing presence in immunology is focused on five mid- to late-stage franchises with multi-disease potential, in areas including rheumatology (including systemic lupus erythematosus), dermatology, gastroenterology, and systemic eosinophilic-driven diseases.
The Pharma Data
NOVEMBER 4, 2020
Juyou will be responsible for the overall clinical development and regulatory filings for Pliaglis with the National Medical Products Administration (the “NMPA”, formerly the China State Food and Drug Administration). . LAVAL, QC, Nov. 5, 2020 /PRNewswire/ – Crescita Therapeutics Inc.
Expert insights. Personalized for you.
72 
Let's personalize your content